NEW YORK (GenomeWeb News) — Invitrogen and Progenitor Cell Therapy today said they will co-develop and -market Invitrogen’s media and cell separation technologies, PCT said today.
The agreement will include marketing, co-referrals, joint proposals, and technical consulting around Invitrogen’s Dynabeads and Dynabeads ClinExVivo, which are ex vivo T-cell and immune-functioning technologies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.